Practice Management
In a study of 9,258 adults with type 2 diabetes, frequent continuous glucose monitoring (CGM) use was linked to significantly greater HbA1C reductions over 12 months compared with no CGM use, as published in JAMA Network Open. Patients using their CGM devices on 270 days per year or more achieved a mean HbA1C decrease of −1.52 percentage points (95% confidence interval [CI], −1.73 to −1.32 percentage points) vs −0.63 percentage points in nonusers (95% CI, …
Read More
About 40% of patients in the University of Colorado Health system who were prescribed a glucagon-like peptide-1 (GLP-1) receptor agonist over a nearly 4 year time span did not fill the prescription, according to a research letter in JAMA Health Forum. Researchers analyzed 9,848 orders for 6,094 unique patients between January 2018 and September 2022, finding that overall, 5,915 (60.1%) orders were filled within 90-days. Patients with both diabetes and obesity were more likely to …
Read More
Over the past few weeks, glucagon-like peptide-1 agonist (GLP-1) drug manufacturers Eli Lilly and Novo Nordisk have been sending cease and desist notices to providers that are still advertising generic, compounded versions of their brand name diabetes and weight loss drugs. A shortage of GLP-1 drugs temporarily allowed compounding pharmacies to produce their own versions, but now with the shortage over, the pharmacies must stop and return to filling prescriptions with the manufacturers’ branded products. …
Read More
Patients are finding positive benefit in the use of glucagon-like peptide 1 (GLP-1) receptor agonist drugs across a wide range of health conditions, as published in Nature Medicine. An observational study of Veterans Affairs data for nearly 2 million patients found that over about 3 years, adults with type 2 diabetes who used a GLP-1 had significantly decreased risks for 42 outcomes, increased risks for 19 outcomes, and no effect with 114 other outcomes when …
Read More
In a pharmaceutical head-to-head, tirzepatide was found to provide 47% greater relative weight loss compared to semaglutide. On average, patients using tirzepatide lost 50.3 lbs (22.8 kg), and those using semaglutide lost 33.1 lbs (15.0 kg) after 72 weeks. In addition, for the study’s secondary endpoint, 31.6% of people taking tirzepatide achieved at least 25% body weight loss compared to 16.1% of those taking semaglutide. The randomized, open-label trial included 751 participants across the United …
Read More
Patients taking glucagon-like peptide-1 (GLP-1) drugs like semaglutide for diabetes may have a lower risk of opioid drug overdose, according to a new study led by National Institute on Drug Abuse Director Nora Volkow, MD, published in JAMA Network Open. Previous empirical studies and anecdotal reports of fewer drug cravings among individuals with type 2 diabetes and comorbid opioid use disorder who use semaglutide inspired the study. Because the GLP-1 drugs are relatively new, there …
Read More
A nationwide population-based study on prescribing trends published in the Annals of Internal Medicine found a significant increase in new users of GLP-1 receptor agonists who don’t have a diagnosis of type 2 diabetes. The proportion of new GLP-1 users with type 2 diabetes decreased from nearly 90% to about 70% from 2019 to 2023, according to a separate analysis of the findings in MedPage Today. Meanwhile, new users tend to be those prescribed the …
Read More
Drugmakers are developing new iterations of GLP-1 weight loss drugs that could result in fewer side effects. According to a news item in Becker’s Hospital Review, 27 GLP-1 drugs are in development, but the majority of the data is based on animal studies or early-stage human trials. In one example, researchers are optimistic about the experimental drug petrelinitide, which was shown to reduce body weight by an average of nearly 9% at 16 weeks. It …
Read More